GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Precision BioSciences Inc (NAS:DTIL) » Definitions » Accounts Receivable

Precision BioSciences (Precision BioSciences) Accounts Receivable : $0.90 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Precision BioSciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Precision BioSciences's accounts receivables for the quarter that ended in Dec. 2023 was $0.90 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Precision BioSciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 11.68.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Precision BioSciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-5.66.


Precision BioSciences Accounts Receivable Historical Data

The historical data trend for Precision BioSciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Precision BioSciences Accounts Receivable Chart

Precision BioSciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial 0.97 10.00 0.49 0.72 0.90

Precision BioSciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.69 0.65 3.51 0.90

Precision BioSciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Precision BioSciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Precision BioSciences's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0.901/7.038*91
=11.68

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Precision BioSciences's accounts receivable are only considered to be worth 75% of book value:

Precision BioSciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(116.678+0.75 * 0.901+0.5 * 0-140.92
-0-0)/4.16404
=-5.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Precision BioSciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Precision BioSciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Precision BioSciences (Precision BioSciences) Business Description

Traded in Other Exchanges
Address
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Executives
J. Jefferson Smith 10 percent owner C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Alan List officer: Chief Medical Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Michael Amoroso director, officer: President and CEO 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Dario Scimeca officer: General Counsel C/O PRECISION BIOSCIENCES, INC., 302 E. PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
John Alexander Kelly officer: Interim CFO C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Pharma Ag Novartis 10 percent owner LICHTSTRASSE 35, CH-4002, BASEL V8
Ag Novartis 10 percent owner LICHTSTRASSE 35, BASEL V8 CH 4056
Derek Jantz director, 10 percent owner, officer: Chief Scientific Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Melinda Brown director 10 HUDSON YARDS, NEW YORK NY 10001
Shari Lisa Pire director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Samuel C. Wadsworth director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
David S. Thomson officer: Chief Development Officer C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Stanley Frankel director C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701
Matthew R. Kane director, 10 percent owner, officer: President and CEO C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, SUITE A-100, DURHAM NC 27701
Shane Barton officer: VP & Corporate Controller C/O PRECISION BIOSCIENCES, INC., 302 EAST PETTIGREW STREET, DURHAM NC 27701